Teva Pharma Industries Ltd ADR (TEVA) Fair Value & Analysis

Healthcare · US · Market cap $37.5B · ISIN US8816242098

What is Teva Pharma Industries Ltd ADR really worth?

Teva Pharma Industries Ltd ADR TEVA · US

Price$36.62

Fair Value$15.33

Upside−58.1%

Quality50/100

A solid business, but trading 139% above our fair value of $15.33.

Watch Teva Pharma Industries Ltd ADR for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Risks

!Weak Growth (revenue 5y +0.7 %/yr)

!Thin margins · 9.0% net margin

!High debt · generates free cash flow

!Mixed vs. peers (6/15)

!Moderate moat 53/100

!The models disagree: range $8.15 to $27.49

!Weak on future: 12 out of 100

!Weak on balance sheet: 5 out of 100

Evidence: High Range $8.15 – $27.49

Fair value as of: Sep 2, 2026

From 26 valuation models · updated 2 days ago

Share price +6.4% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

The price sits above even our optimistic bull case ($27.49). The favourable scenario is already priced in.
The model range is unusually wide ($8.15 to $27.49). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 2, 2026.

How to read this chart

60‑month range $6.86 – $38.10 · fair‑value band $8.15 – $27.49 · the $36.62 price screens above the $15.33 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 2, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Teva Pharma Industries Ltd ADR (TEVA) currently trades at $36.62, while our model-based Fair Value estimate is $15.33, implying the stock looks roughly 138.9% overvalued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of $24.52 per share, and 0 of the 26 models we run sit above the $36.62 price. Bear case: the Asset-Based group reads lowest at $4.55, and 26 of the 26 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Teva Pharma Industries Ltd ADR generated revenue of $17.3B at a net margin of 9.0%. Revenue grew 2.3% year over year. It earns a return on equity of 21.6%. Net debt stands at $13.8B. Fundamentals as of Sep 2, 2026

Our scenario range runs from $8.15 (bear case) to $27.49 (bull case); at $36.62, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 2% below its 52-week high and 144% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −58%, TEVA screens richer than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $0.9068 per share, which is 5.9 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence

Highest evidence

EPV $6.06 $8.71 $11.02 73

FCF DCF $1.76 $8.94 $20.30 72

Owner Earnings $9.45 $21.41 $40.32 72

All 26 models by family

DCF Models

FCF DCF $1.76 $8.94 $20.30 72

Owner Earnings $9.45 $21.41 $40.32 72

5Y Revenue Exit $4.82 $15.21 $28.79 68

5Y EBITDA Exit $11.00 $27.06 $46.34 72

5Y P/E Exit $5.96 $17.39 $29.71 67

10Y Revenue Exit $3.10 $12.41 $25.55 61

10Y EBITDA Exit $7.60 $20.75 $39.27 64

10Y P/E Exit $4.36 $13.94 $26.27 59

Earnings-Based

Graham-Dodd $8.23 $28.96 $38.96 64

Lynch FV $6.76 $9.66 $12.56 61

PEG = 1.0 $6.76 $9.66 $12.56 57

EPV $6.06 $8.71 $11.02 73

Dividend Discount

Gordon GGM $0.4100 $0.8500 $1.35 66

DDM Multi-Stage $0.4100 $0.7200 $0.8900 67

Multiples

P/E Multiple $19.98 $26.64 $33.30 63

P/S Multiple $15.44 $20.59 $25.73 58

P/B Multiple $15.44 $20.59 $25.73 55

EV/EBIT $13.80 $21.67 $29.55 64

EV/EBITDA $18.67 $28.16 $37.66 66

EV/Revenue $7.04 $14.27 $21.49 51

Asset-Based

NCAV (Graham) $3.40 $4.55 $6.79 54

Growth DCF

Growth DCF $1.89 $8.10 $17.23 71

Rev-Margin DCF $4.82 $15.03 $27.13 68

Economic Profit

Residual Income $8.07 $11.22 $48.94 64

ROIC Compounder $6.06 $10.08 $15.92 69

Growth Earnings

Growth-Adj P/E $17.17 $24.52 $31.88 67

Widest divergence: Growth Earnings ($24.52) versus Dividend Discount ($0.7200). Highest evidence: EPV (73).

Notify me when TEVA reaches fair value

Put TEVA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 27.3

P/S ratio 2.23 P/E × margin

EPS (TTM) $1.34 price ÷ EPS = P/E 27.3

Dividend yield 0.1% payout 3.8%

Net margin 8.2% FY2025

Return on equity 21.6% TTM

More key figures

Profitability

Return on assets (EBIT) 0.8% avg 5y

Operating margin 19.2% TTM

Growth

Revenue (TTM) $17.3B TTM

Revenue growth (YoY) +2.3% 3y avg +5.0%

EPS growth (YoY) +72.2%

Balance sheet & cash flow

Free cash flow $1.1B FY2025

Net debt $13.8B FY2025 · ≈ 12.0 yrs of FCF

Figures from reported company fundamentals · as of Sep 2, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 50/100

Of which business quality 46 · Market factors (momentum, volatility) 75

Profitability 41

Margins and returns on capital today

Quality Growth 53

Are margins and returns improving?

Cashflow 46

Earnings quality: real cash, not paper profit

Fin. Strength 12

Balance sheet, leverage, solvency risk

Investment 98

Disciplined investing over empire-building

Low Volatility 60

Calm price path (market factor)

Momentum 72

Price trend over the last 3–12 months (market factor)

52W Momentum 98

Distance to the 52-week high (market factor)

Net Issuance 54

Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Full company description

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Teva Pharma Industries Ltd ADR reported revenue of $17.3B in FY2025 versus $15.9B in FY2021, a compound +2.1%/yr. Reported net income was $1.4B in FY2025, compounding +35.6%/yr from FY2021.

Growth Quality 40/100

Revenue growth is weak, negative or inconsistent.

Latest Revenue (FY 2025)

$17.3B

Latest YoY

+4.3%

Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

+5.0%

Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

+0.7%

Avg. revenue growth/yr (40Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

+14.0%

Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.

+26.2% (26.1 + 0.1)

Revenue +2.1%/yr

FY21 $15.9B

FY22 $14.9B

FY23 $15.8B

FY24 $16.5B

FY25 $17.3B

Net income +35.6%/yr

FY21 $417M

FY22 −$2.4B

FY23 −$559M

FY24 −$1.6B

FY25 $1.4B

TEVA screens 139% overvalued. Compare with Merck KGaA →

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

Share or link this analysis

𝕏 Post WhatsApp LinkedIn Reddit

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Teva Pharma Industries Ltd ADR · Fair Value
$15.33 −139%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/TEVA" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Teva Pharma Industries Ltd ADR · Fair Value</span><br><b style="font-size:20px">$15.33</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−139%</span></span><span style="font-size:11px;color:#7BB290;font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Teva Pharma Industries Ltd ADR Fair Value". https://www.fairvalue-calculator.com/stock/TEVA

Peer Group

Drug Manufacturers - Specialty & Generic · 608 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 50 · Below median

Fair Value upside −58% · Below median

Return on equity (TTM) 22% · Top 25%

Return on assets 6% · Top 25%

Net margin (TTM) 9% · Above median

Operating margin (TTM) 19% · Top 25%

Revenue growth 2% · Below median

Dividend yield (TTM) 0.1% · Bottom 25%

Debt / equity 1.90× · Higher than 75% of peers

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 27.3× · Pricier than median

P/B 4.74× · Pricier than 75% of peers

P/S (TTM) 2.16× · Pricier than median

P/FCF 32.7× · Pricier than 75% of peers

EV/EBITDA 9.8× · Cheaper than median

PEG 0.92× · Cheaper than median

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

This stock

Sector peers

VALUE0 · sector 2

FUTURE12 · sector 22

PAST86 · sector 26

HEALTH5 · sector 97

DIVIDEND3 · sector 29

VALUE 0: the price sits above our fair-value range.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Sep 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€140.25	€106.48	−24%
Takeda Pharmaceutical Company TAK	$18.03	$11.11	−38%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥53.76	¥25.94	−52%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,944	₹989.50	−49%
Galderma Group GALD	CHF 178.55	CHF 55.07	−69%
Haleon plc HLN	$10.11	$7.64	−24%
Sandoz Group SDZ	CHF 70.66	CHF 39.21	−45%
Zoetis Inc ZTS	$77.10	$104.88	+36%
Hansoh Pharmaceutical Group 3692	HK$35.12	HK$16.18	−54%
Divi's Laboratories Limited DIVISLAB	₹8,525	₹1,228	−86%

Compare Teva Pharma Industries Ltd ADR with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Teva Pharma Industries Ltd ADR (TEVA) overvalued or undervalued?

As of Sep 2, 2026, our model estimates a fair value of $15.33 versus a price of $36.62, about −58% upside (overvalued).

What is the fair value of TEVA?

Our model-based fair value for Teva Pharma Industries Ltd ADR is $15.33 (as of Sep 2, 2026), built from audited fundamentals. The current price: $36.62.

What is the quality score of TEVA?

Teva Pharma Industries Ltd ADR has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the revenue of Teva Pharma Industries Ltd ADR (TEVA)?

Teva Pharma Industries Ltd ADR reported trailing-twelve-month revenue of about $17.3B (latest available figure, as of Sep 2, 2026).

What is the net profit margin of TEVA?

The net profit margin of Teva Pharma Industries Ltd ADR is about 9.0%, meaning it keeps roughly 9.0% of revenue as net income. Based on the latest reported figures.

Does Teva Pharma Industries Ltd ADR pay a dividend?

Teva Pharma Industries Ltd ADR currently shows a dividend yield of about 0.14% relative to its recent price (as of Sep 2, 2026).

Free · no account needed

Watch Teva Pharma Industries Ltd ADR in the live analysis

One click puts Teva Pharma Industries Ltd ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.